Show simple item record

dc.contributor.authorZivin, Kara
dc.contributor.authorKim, H. Myra
dc.contributor.authorYosef, Matheos
dc.contributor.authorMaust, Donovan T.
dc.contributor.authorValenstein, Marcia
dc.contributor.authorSmith, Eric G.
dc.contributor.authorDavydow, Dimitry S.
dc.date2022-08-11T08:10:30.000
dc.date.accessioned2022-08-23T17:11:19Z
dc.date.available2022-08-23T17:11:19Z
dc.date.issued2016-10-01
dc.date.submitted2017-04-13
dc.identifier.citationJ Clin Psychopharmacol. 2016 Oct;36(5):445-52. doi: 10.1097/JCP.0000000000000545. <a href="https://doi.org/10.1097/JCP.0000000000000545">Link to article on publisher's site</a>
dc.identifier.issn0271-0749 (Linking)
dc.identifier.doi10.1097/JCP.0000000000000545
dc.identifier.pmid27580492
dc.identifier.urihttp://hdl.handle.net/20.500.14038/46248
dc.description.abstractOBJECTIVE: Although previous studies have assessed whether depression is a mortality risk factor, few have examined whether antidepressant medications (ADMs) influence mortality risk. METHODS: We estimated hazards of 1-year all-cause mortality associated with ADMs, with use occurring within 90 days of depression diagnosis among 720 821 patients who received treatment in a Veterans Health Administration facility during fiscal year 2006. We addressed treatment selection biases using conventional Cox regression, propensity-stratified Cox regression (propensity score), and 2 forms of marginal structural models. Models accounted for multiple potential clinical and demographic confounders, and sensitivity analyses compared findings by antidepressant class. RESULTS: Antidepressant medication use compared with no use was associated with significantly lower hazards of 1-year mortality risk in Cox (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.90-0.97) and propensity score estimates (HR, 0.94; 95% CI, 0.91-0.98), whereas marginal structural model-based estimates showed no difference in mortality risk when the exposure was specified as "as-treated" in every 90-day intervals of the 1-year follow-up (HR, 0.91; 95% CI, 0.66-1.26) but showed increased risk when specified as "intent-to-treat" (HR, 1.07; 95% CI, 1.02-1.13). CONCLUSIONS: Among patients treated with ADMs belonging to a single class in the first 90 days, there were no significant differences in 1-year all-cause mortality risks. When accounting for clinical and demographic characteristics and treatment selection bias, ADM use was associated with no excess harm.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27580492&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1097/JCP.0000000000000545
dc.subjectMedical Pharmacology
dc.subjectMental and Social Health
dc.subjectPsychiatry
dc.subjectPsychiatry and Psychology
dc.titleAntidepressant Medication Treatment and Risk of Death
dc.typeJournal Article
dc.source.journaltitleJournal of clinical psychopharmacology
dc.source.volume36
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/785
dc.identifier.contextkey10015285
html.description.abstract<p>OBJECTIVE: Although previous studies have assessed whether depression is a mortality risk factor, few have examined whether antidepressant medications (ADMs) influence mortality risk.</p> <p>METHODS: We estimated hazards of 1-year all-cause mortality associated with ADMs, with use occurring within 90 days of depression diagnosis among 720 821 patients who received treatment in a Veterans Health Administration facility during fiscal year 2006. We addressed treatment selection biases using conventional Cox regression, propensity-stratified Cox regression (propensity score), and 2 forms of marginal structural models. Models accounted for multiple potential clinical and demographic confounders, and sensitivity analyses compared findings by antidepressant class.</p> <p>RESULTS: Antidepressant medication use compared with no use was associated with significantly lower hazards of 1-year mortality risk in Cox (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.90-0.97) and propensity score estimates (HR, 0.94; 95% CI, 0.91-0.98), whereas marginal structural model-based estimates showed no difference in mortality risk when the exposure was specified as "as-treated" in every 90-day intervals of the 1-year follow-up (HR, 0.91; 95% CI, 0.66-1.26) but showed increased risk when specified as "intent-to-treat" (HR, 1.07; 95% CI, 1.02-1.13).</p> <p>CONCLUSIONS: Among patients treated with ADMs belonging to a single class in the first 90 days, there were no significant differences in 1-year all-cause mortality risks. When accounting for clinical and demographic characteristics and treatment selection bias, ADM use was associated with no excess harm.</p>
dc.identifier.submissionpathpsych_pp/785
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages445-52


This item appears in the following Collection(s)

Show simple item record